Patient and donor characteristics
| Characteristics . | Value . |
|---|---|
| HLA locus matching match/mismatch, no. (%) | |
| HLA-A | 7048 (89)/850 (11) |
| HLA-B | 7475 (95)/423 (5) |
| HLA-C | 5565 (70)/2333 (30) |
| HLA-DRB1 | 5878 (74)/2020 (26) |
| HLA-DQB1 | 5681 (72)/2217 (28) |
| HLA-DPB1 | 2604 (33)/5294 (67) |
| Patient age, y | |
| Median (range) | 35 (0-77) |
| Donor age, y | |
| Median (range) | 34 (20-56) |
| Disease, no. (%) | |
| Acute lymphoblastic leukemia | 1861 (24) |
| Acute myeloblastic leukemia | 2609 (33) |
| Chronic myeloid leukemia | 983 (12) |
| Myelodysplastic syndrome | 841 (11) |
| Other leukemia | 312 (4) |
| Lymphoid malignancy | 542 (7) |
| Aplastic anemia | 489 (6) |
| Multiple myeloma | 33 (<1) |
| Others | 228 (3) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine based | 3078 (39) |
| Tacrolimus based | 4779 (61) |
| Others | 41 (<1) |
| Leukemia risk, no. (%) | |
| Standard | 2508 (32) |
| High | 2772 (35) |
| N/A | 2618 (33) |
| Conditioning, no. (%) | |
| Myeloablative | 6653 (84) |
| Reduced intensity | 1245 (16) |
| Sex matching (donor to patient), no. (%) | |
| Female to male | 1494 (19) |
| Male to male | 3253 (41) |
| Female to female | 1442 (18) |
| Male to female | 1709 (22) |
| Transplanted year period, no. (%) | |
| 1993-2000 | 2311 (29) |
| 2001-2005 | 3084 (39) |
| 2006-2010 | 2503 (32) |
| Characteristics . | Value . |
|---|---|
| HLA locus matching match/mismatch, no. (%) | |
| HLA-A | 7048 (89)/850 (11) |
| HLA-B | 7475 (95)/423 (5) |
| HLA-C | 5565 (70)/2333 (30) |
| HLA-DRB1 | 5878 (74)/2020 (26) |
| HLA-DQB1 | 5681 (72)/2217 (28) |
| HLA-DPB1 | 2604 (33)/5294 (67) |
| Patient age, y | |
| Median (range) | 35 (0-77) |
| Donor age, y | |
| Median (range) | 34 (20-56) |
| Disease, no. (%) | |
| Acute lymphoblastic leukemia | 1861 (24) |
| Acute myeloblastic leukemia | 2609 (33) |
| Chronic myeloid leukemia | 983 (12) |
| Myelodysplastic syndrome | 841 (11) |
| Other leukemia | 312 (4) |
| Lymphoid malignancy | 542 (7) |
| Aplastic anemia | 489 (6) |
| Multiple myeloma | 33 (<1) |
| Others | 228 (3) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine based | 3078 (39) |
| Tacrolimus based | 4779 (61) |
| Others | 41 (<1) |
| Leukemia risk, no. (%) | |
| Standard | 2508 (32) |
| High | 2772 (35) |
| N/A | 2618 (33) |
| Conditioning, no. (%) | |
| Myeloablative | 6653 (84) |
| Reduced intensity | 1245 (16) |
| Sex matching (donor to patient), no. (%) | |
| Female to male | 1494 (19) |
| Male to male | 3253 (41) |
| Female to female | 1442 (18) |
| Male to female | 1709 (22) |
| Transplanted year period, no. (%) | |
| 1993-2000 | 2311 (29) |
| 2001-2005 | 3084 (39) |
| 2006-2010 | 2503 (32) |
Patient and donor characteristics by HLA locus matching are shown in supplemental Table 1.
N/A, not applicable.